Hommos Musab S, Elugunti Praneetha, Pullee Amanda M, Walker Clay W, Drechsel Karen S, Pinello Stephanie R, Fillers Andrea, Khera Nandita, Paul Margaret M
Division of Nephrology and Hypertension, Mayo Clinic, Scottsdale, AZ.
Department of Administration, Mayo Clinic, Phoenix, AZ.
Mayo Clin Proc Innov Qual Outcomes. 2025 May 30;9(4):100629. doi: 10.1016/j.mayocpiqo.2025.100629. eCollection 2025 Aug.
To describe the development and deployment of a remote patient monitoring (RPM) program for hypertension and to share outcomes from an initial cohort of patients enrolled in this program.
The development of an RPM program for hypertension is described in detail. A sample of patients who were enrolled in RPM, participated for at least 2 weeks, and completed the program from January 1, 2023, to December 31, 2023, were included in the analysis. Clinical data were summarized using descriptive statistics. For comparing continuous variables, the independent samples test was employed. For analyzing relationships between categorical variables, the χ test was utilized.
Total of 101 patients met the inclusion criteria. The median age was 69 years with a range from 22 to 95 years; 51 (51%) were men, 93 (92%) were White, and 6 (6%) identified as Hispanic. The median length of participation in the program was 38 days, with a range from 18 to 160 days. The average blood pressure decreased during program enrollment from 153/84 to 126/75 mm Hg (<.001), whereas heart rate decreased from 73 to 70 bpm (=.03). On average, the number of antihypertensive drugs increased from 2.06 to 2.3 (=.02). On average, clinicians received 1.1 messages per week per enrolled patient in RPM.
Developing and implementing an RPM program for hypertension is feasible with adequate resources, planning, and piloting. These programs are associated with clinically significant improvements in blood pressure control for patients with hypertension without considerably increasing calls and messages from patients beyond routine care.
描述高血压远程患者监测（RPM）项目的开发与实施，并分享该项目首批入组患者的结果。
详细描述了高血压RPM项目的开发过程。分析纳入了2023年1月1日至2023年12月31日期间入组RPM、参与至少2周并完成该项目的患者样本。临床数据采用描述性统计进行总结。比较连续变量时，采用独立样本t检验。分析分类变量之间的关系时，使用χ检验。
共有101例患者符合纳入标准。年龄中位数为69岁，范围为22至95岁；51例（51%）为男性，93例（92%）为白人，6例（6%）为西班牙裔。参与该项目的时间中位数为38天，范围为18至160天。在项目入组期间，平均血压从153/84降至126/75 mmHg（P<.001），而心率从73次/分钟降至70次/分钟（P=.03）。平均而言，降压药数量从2.06种增加至2.3种（P=.02）。平均而言，在RPM中，临床医生每周从每位入组患者处收到1.1条信息。
在有足够资源、规划和试点的情况下，开发和实施高血压RPM项目是可行的。这些项目与高血压患者血压控制的临床显著改善相关，且不会在常规护理之外大幅增加患者的呼叫和信息。
